Abbott's PCR instrument will help the biopharma companies identify isocitrate dehydrogenase mutations in patients with acute myeloid leukemia.
The court order provided a schedule of actions designed to resolve antitrust issues related to the deal.
The companies appear poised to return to court to settle Alere's claim that Abbott needs to quickly fulfill its obligations under their merger deal.
The Alere flu test detected fewer cases of influenza A in a recent study, which researchers attributed to low viral loads.
The firm's confirmation that it is on track with current and Q3 financial report timing may not be enough to appease would-be acquirer Abbott.
Alere filed a legal complaint in order to push Abbott to obtain the anti-trust approvals needed to complete the acquisition proposed earlier this year.
Although the financial filing sheds increased light on Alere's business, the company is asking for an extension to file its second quarter financial statements.
While Abbott continues to express concerns about the pending acquisition, Alere has remained resolute in its response.
The firm also reported that it has corrected immaterial errors in previous financial statements.
The company said in December that it had identified a new pegivirus, and is now using that work to redesign an assay that could show how the virus acts in humans.
A new report offers ways for small, society publishers to transition to Plan S standards, ScienceInsider says.
A gas explosion sparked a fire at a Russian laboratory that stores dangerous pathogens, the Guardian reports.
Researchers turn to protein analysis to examine an ancient rhino sample, Smithsonian.com reports.
In PNAS this week: C2CD4A gene involved in insulin secretion, chromosome rearrangements in recurring S. aureus infections, and more.